AZN AstraZeneca PLC

$AZN $JNJ $SLS Part 2. Everyone here is so fixated with the victory lap booth size that they forgot that $SLS quiet period just passed 3 months this week. $SLS didn’t renew the lease for another year to 2028 like they have been doing every year since inception. Remember under strict NDA they don’t need to disclose anything right before a BO. You all can read about it in the final 10k. $SLS GPS Breakthrough Success is a forgone conclusion. My money is on $JNJ perfect fit for both GPS and SLS009. ✌️🙏❤️‍🩹

$AZN $SLS $SMMT Part 3. Summit Therapeutics $SMMT shares nearly doubling this week after its lung cancer drug beat Merck's Keytruda in a head-to-head trial. ✌️🙏❤️‍🩹

$AZN AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care."

$AZN AstraZeneca has announced they will invest $2,000,000,000 in Summit Therapeutics $SMMT, to bet on their cancer drug Ivonescimab 📈

AstraZeneca has agreed to make a strategic $2 billion equity investment in Summit Therapeutics, strengthening a broader collaboration centered on Summit’s lead bispecific antibody, ivonescimab. Under the deal, AstraZeneca will purchase convertible preferred shares equivalent to $18.36 per common share, a 10% premium to Summit’s five-day volume-weighted average price. The investment will strengthen Summit’s balance sheet and support its global clinical development efforts, while giving AstraZeneca a strategic stake in next-generation oncology therapies. The companies will also conduct a clinical trial combining ivonescimab with AstraZeneca’s investigational antibody-drug conjugate sonesitatug vedotin in gastrointestinal cancers, sharing study costs with AstraZeneca serving as sponsor. The companies also signed a nonbinding memorandum to explore combining ivonescimab with additional AstraZeneca oncology treatments, including its broader ADC portfolio. $AZN $SMMT

$AZN Astrazeneca. This is such a good hedge against tech stocks. When they tumble this usually goes higher.

HUTCHMED announced Tuesday that AstraZeneca has submitted an application to the U.S. FDA seeking approval of the ORPATHYS-TAGRISSO combination for patients with advanced lung cancer. The filing marks a further regulatory step for the companies’ collaboration in targeted oncology treatments. HUTCHMED and AstraZeneca jointly develop ORPATHYS, while AstraZeneca is responsible for its commercialization. The proposed combination brings ORPATHYS together with TAGRISSO, AstraZeneca’s targeted cancer therapy, as the companies seek to expand treatment options for patients with advanced disease. The FDA application will now enter the regulatory review process, with investors monitoring the agency’s assessment and any subsequent milestones that could affect the commercial outlook for the collaboration. $AZN

$AZN (AstraZeneca) will invest $2.X billion in Summit Therapeutics to collaborate on cancer drug studies, pairing Summit's ivonescimab with AstraZeneca's oncology pipeline; Summit shares surged over 15% after-hours on the deal.

$AZN Advanced research on certain serious diseases. (High attention on what AstraZeneca currently works on)

📈 $AZN — AstraZeneca Technical Analysis: AZN is showing a strong rebound after yesterday's sharp sell-off. The stock moved from around $155.82 to above $161 today, creating a strong bullish recovery candle. The key near-term resistance zone is around $162–$164. A clean breakout above this area, supported by increasing volume, could open the door toward $166–$168. Volume is important here: today's move is bullish, but confirmation with stronger-than-average volume would make the setup considerably stronger. 🤖 AI View: Bullish Recovery 🎯 SST Score: 82/100 — BULLISH Potential setup: Entry: $161–$163 after confirmation Target 1: $166 Target 2: $168–$170 Stop: Below $157.50 AI signal: 🟢 BULLISH — breakout confirmation preferred

🚀 STOCKS TO WATCH TODAY! 🚀 🔥 4 STOCKS ON OUR RADAR 📈 $AZN – AstraZeneca A major pharmaceutical player with strong long-term growth potential. Keep an eye on bullish momentum and a possible continuation move. 📈 $AXSM – Axsome Therapeutics An interesting biotech growth stock. Watch for increasing volume, momentum expansion and a potential breakout. 📈 $ARGX – argenx A strong player in the biotech sector. Monitor price action for renewed buying pressure and a possible bullish continuation. 📈 $AZN | $AXSM | $ARGX 🎯 SST Trading Strategy: We focus on short-term swing trading opportunities, targeting potential moves over the next 3–5 trading days. ✅ Watch for strong BUY signals ✅ Confirm momentum with volume ✅ Identify breakout opportunities ✅ Always manage risk with a stop-loss Structure, not emotion. Trade smart with SST! 🐂 #StocksToWatch #StockMarket #SwingTrading #DayTrading #StockSignals #BiotechStocks #AstraZeneca #AXSM #ARGX #SST

$AZN What the Hell…….When are you coming to Cytovia, Immune Pharmaceuticals and Maxim Pharmaceuticals to clean up my rights with Oakpoint? I don’t care what device you use. I know where you stashed the candy rights. You can’t hide from this crazy nutbag. Are you done circle jerking with my rights? Can you make this fucking deal happen already. You bought my shit in BK and now it’s time for the Legacy share residual rights ( consideration rights / contractual rights ) to be acknowledged. I don’t care what the fuck your planning in 2030. I want my fucking money. Use Satellos. Use ICO Therapeutics. However you want to do it. Pick a pure play. I feel Mr. Marc de Garidel is doing some dirty shit for you people again weaving amongst those assets. It’s obvious you like our goods. Nice. But stop peering in the windows. Get in that room and fuck a shell. Thank you very much. Now finish the deal you Russian Beaver. Stop chopping the wood and build some shit. Ck

*September 29, 2026 Opening Bell Rundown* - Anthropic's IPO filing is boosting Al-sector attention after the company disclosed plans for a potential valuation above $2 trillion despite enormous losses and spending requirements. - OpenAl reportedly delayed its upcoming GPT-6.1 Astra launch after concerns emerged during testing. - Summit Therapeutics is surging roughly 20% PM after AstraZeneca announced a $2 billion investment and collaboration on cancer-treatment studies. $AZN $SMMT - AMD is acquiring World Labs in a deal valued at $8.2 billion, developing “world models” designed to simulate and understand 3D environments. $AMD Have a great day! 😊